Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a ...

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and ...

MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

Tumors in the human body contain immune cells called macrophages that are naturally capable of attacking cancer. However, ...

On this World Cancer Day, we look at where research and availability stand for cancer vaccines.

Pelareorep is also showing strong results in anal cancer, where third-line patients achieved a 29% response rate with responses lasting around 17 months in a setting with no FDA-approved treatments.

A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

Rising investment in individualized cancer therapies, expanding mRNA and AI-driven antigen discovery platforms, and accelerating clinical success are creating high-value opportunities for stakeholders ...